Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. KMDA
KMDA logo

KMDA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Kamada Ltd (KMDA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
8.190
1 Day change
-0.97%
52 Week Range
9.350
Analysis Updated At
2026/04/24
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Kamada Ltd (KMDA) is not a strong buy at the moment for a beginner investor with a long-term focus. The stock lacks significant positive catalysts, and technical indicators do not suggest a compelling entry point. While the company's revenue growth is promising, declining net income and gross margin are concerns. The absence of trading signals and recent news further supports a cautious approach.

Technical Analysis

The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 45.437, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 8.36, with support at 8.176 and resistance at 8.543.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
5
Buy
6

Positive Catalysts

  • Revenue increased by 14.54% YoY in Q4 2025, indicating growth potential.

Neutral/Negative Catalysts

  • Net income dropped by 6.46% YoY, and gross margin decreased by 13.01% YoY. No recent news or significant trading activity from insiders, hedge funds, or Congress.

Financial Performance

In Q4 2025, revenue increased to $44.68M (+14.54% YoY), but net income dropped to $3.56M (-6.46% YoY). EPS remained flat at 0.06, and gross margin declined to 37.98% (-13.01% YoY).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target updates available.

Wall Street analysts forecast KMDA stock price to rise
2 Analyst Rating
Wall Street analysts forecast KMDA stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.270
sliders
Low
13
Averages
14
High
15
Current: 8.270
sliders
Low
13
Averages
14
High
15
H.C. Wainwright
Buy
maintain
$11 -> $13
AI Analysis
2025-12-09
Reason
H.C. Wainwright
Price Target
$11 -> $13
AI Analysis
2025-12-09
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Kamada to $13 from $11 and keeps a Buy rating on the shares. The company decided to discontinue its Phase 3 inhaled alpha-1 antitrypsin deficiency clinical trial based on the results of the planned interim futility analysis, the analyst tells investors in a research note. The firm says the decision helps to refocus the company on its core products and eliminates a "long over-hanging distraction that was unlikely to be fruitful."

People Also Watch